Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases

Shieh Yueh Yang*, Ming Jang Chiu, Ta Fu Chen, Chin Hsien Lin, Jiann Shing Jeng, Sung Chun Tang, Yen Fu Lee, Che Chuan Yang, Bing Hsien Liu, Hsin Hsien Chen, Chau Chung Wu

*此作品的通信作者

研究成果: 雜誌貢獻期刊論文同行評審

37 引文 斯高帕斯(Scopus)

摘要

Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.

原文英語
文章編號9304
期刊Scientific reports
7
發行號1
DOIs
出版狀態已發佈 - 2017 12月 1
對外發佈

ASJC Scopus subject areas

  • 多學科

指紋

深入研究「Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases」主題。共同形成了獨特的指紋。

引用此